OraSure rises as seen benefitting from 23andMe/Regeneron deal

1 month ago 3

• Healthcare
• M&A

Zhanna Hapanovich/iStock via Getty Images

• OraSure Technologies (NASDAQ:OSUR) is up ~6% Monday as it is seen as a beneficiary of Regeneron Pharmaceuticals' (NASDAQ:REGN) deal, announced earlier in the day, to purchase substantially all the assets of genetic testing company 23andMe.
• OraSure, which is engaged in the

Recommended For You

More Trending News

See More »

1. Homepage
2. Politics
3. OraSure rises as seen benefitting from 23andMe/Regeneron deal